In vitro models for testing of cytostatic agents in small cell lung cancer

摘要: Small cell lung cancer (SCLC) is one of the solid tumors most responsive to chemotherapy. Despite apparent initial sensitivity SCLC, acquired drug resistance major problem; only a small proportion patients will remain in remission beyond two years [1]. The overall treatment results have not changed markedly last decade, despite application numerous combination regimens, late intensification high-dose chemotherapy with autologous bone-marrow rescue, and various types adjuvant radiotherapy. Resistance SCLC may be associated concomitant occurrence less chemosensitive histological tumor type, such as adenocarcinoma or squamous carcinoma, but minority cases. large majority (over 85%) who after die disease still histology at autopsy [2]. Although pharmacological basis due changes kinetics during therapy, appears primarily cellular factors.